UNLIMITED · UNderstanding Lipid ImmunoMetabolIsm To trEat Disease

Lines connect the coordinator with its partners.

Project objective

The UNLIMITED project addresses the critical challenges of lipid immunometabolism, a rapidly emerging field with transformative potential for treating immune-mediated diseases such as cancer, autoimmunity and metabolic disorders. Lipid metabolism has been recently recognized as a regulator of immune cell function, yet the intricate interactions between lipid pathways and immune responses within tissue-specific microenvironments remain poorly understood. This knowledge gap hampers the development of precision therapies tailored to the metabolic needs of immune cells in diverse tissue niches. To tackle these challenges, UNLIMITED will train 15 Doctoral Candidates in cutting-edge interdisciplinary research, equipping them with expertise spanning immunology, bioinformatics, metabolism, and drug development. A key feature of UNLIMITED training programme is the integration of leading-edge methodologies, such as multi-omics machine learning, single-cell technologies, CRISPR-Cas9, and spatial metabolomics, alongside groundbreaking techniques pioneered by consortium partners, including SCENITH, Met-Flow, click-chemistry, LIPSTIC, and advanced lipidomics. UNLIMITED’s training program emphasizes a holistic, interdisciplinary approach, providing DCs with technical skills, unparalleled expertise, and transferable competencies to thrive in academic and industrial sectors. The project will unlock unprecedented insights into how lipid metabolic pathways regulate immune cell function and adapt to changes in the tissue microenvironment. This knowledge will enable the identification of novel therapeutic targets and pioneering precision therapies for immune-related diseases. This bold initiative strengthens Europe’s leadership in health innovation, creating a new generation of highly skilled researchers ready to transform global healthcare and advance therapeutic frontiers.

Original text from CORDIS.

Participants

• UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ · MainzCoordinatorGermany
• ACADEMISCH ZIEKENHUIS LEIDEN · LeidenNetherlands
• ActiTrexx GmbH · MainzGermany
• BIOCRATES LIFE SCIENCES AG · INNSBRUCKAustria
• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS · ParisFrance
• CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.) · MadridSpain
• JOHANNES GUTENBERG-UNIVERSITAT MAINZ · MainzGermany
• LUXEMBOURG INSTITUTE OF HEALTH · StrassenLuxembourg
• MEDIZINISCHE UNIVERSITAET WIEN · WienAustria
• SAMPLIX ApS · BIRKERODDenmark
• SANOFI-AVENTIS DEUTSCHLAND GMBH · Frankfurt Am MainGermany
• STICHTING AMSTERDAM UMC · AmsterdamNetherlands
• STICHTING VU · AmsterdamNetherlands
• Sitryx Therapeutics Ltd · OxfordUnited Kingdom
• Sonja NossGermany
• TECHNISCHE UNIVERSITAET BRAUNSCHWEIG · BraunschweigGermany
• THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN · DublinIreland
• THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN · AberdeenUnited Kingdom
• Tress Academic GbR · PlaneggGermany
• UNIVERSIDAD AUTONOMA DE MADRID · MadridSpain
• UNIVERSITA DEGLI STUDI DI MILANO · MilanoItaly
• UNIVERSITA DEGLI STUDI DI PADOVA · PadovaItaly
• UNIVERSITAT ZU KOLN · KolnGermany
• UNIVERSITE D'AIX MARSEILLE · MarseilleFrance
• UNIVERSITE DU LUXEMBOURG · ESCH-SUR-ALZETTELuxembourg
• VILNIAUS UNIVERSITETAS · VilniusLithuania
• VUGENE UAB · KaunasLithuania

Links

• View on CORDIS
• DOI: 10.3030/101227259